drugset / Trial / NCT04875819

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV

NCT04875819

Phase 4 Recruiting 55 enrolled Thomas Benfield
RandomizedCrossoverOpen-labelPrevention

Summary

MENPI is an investigator-initiated single-centre randomized controlled trial which aims to assess the efficacy and safety of meningococcal and pneumococcal vaccination in adults living with HIV receiving antiretroviral treatment. Participants are randomized 1:1 to either a two-dose Menveo® and Bexsero® regimen or a Prevenar13®/Pneumovax23® prime-boost regimen at day 0 and day 60 and cross over on day 90. All participants will follow an identical follow up program including plasma collection, pharyngeal swab, and adverse event registration. Immunogenicity will be determined on venous blood sampled at 30 days post-vaccination and yearly for five years.

Timeline

Start
2021-04-28
Primary completion
2026-12
Completion
2026-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexsero Vaccine 0.5 ml
Subject Menveo Vaccine 0.5 ml
Subject Pneumovax 23 Vaccine 0.5 ml
Subject Prevnar 13 Vaccine 0.5 ml